Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedNov 06, 2025
DataAggregated Company Financials
Companies543
  • 7D1.6%
  • 3M18.1%
  • 1Y1.0%
  • YTD15.4%

The Biotech industry is up 1.6% in the last week, with Amgen up 9.6%. Despite this gain, the industry's performance has been flat over the past year. Earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 06 Nov 2025US$1.1tUS$164.1b-US$16,282,738,859.5217.5x-68.8x6.8x
Sat, 04 Oct 2025US$1.1tUS$163.5b-US$18,206,071,363.5716.7x-61.8x6.9x
Mon, 01 Sep 2025US$1.1tUS$163.5b-US$18,373,688,758.5615.4x-57.4x6.5x
Wed, 30 Jul 2025US$978.3bUS$155.2b-US$22,170,866,971.1715.8x-44.1x6.3x
Fri, 27 Jun 2025US$928.2bUS$156.0b-US$23,838,153,787.8216.8x-38.9x6x
Sun, 25 May 2025US$907.6bUS$155.9b-US$24,118,382,442.0315.6x-37.6x5.8x
Tue, 22 Apr 2025US$757.2bUS$119.3b-US$36,503,635,360.2219.1x-20.7x6.3x
Thu, 20 Mar 2025US$833.1bUS$118.4b-US$37,426,956,446.7520.1x-22.3x7x
Sat, 15 Feb 2025US$843.4bUS$116.6b-US$36,838,403,221.2117.6x-22.9x7.2x
Mon, 13 Jan 2025US$947.7bUS$149.4b-US$26,263,014,335.7116.6x-36.1x6.3x
Wed, 11 Dec 2024US$1.0tUS$150.0b-US$26,535,944,620.1117.9x-39x6.9x
Fri, 08 Nov 2024US$1.1tUS$149.1b-US$31,021,469,881.2517x-35.4x7.4x
Sun, 06 Oct 2024US$889.8bUS$113.1b-US$35,952,253,973.7722x-24.8x7.9x
Tue, 03 Sep 2024US$909.4bUS$113.1b-US$35,704,251,292.6924x-25.5x8x
Thu, 01 Aug 2024US$1.2tUS$165.1b-US$29,392,630,542.9630.2x-41.8x7.4x
Sat, 29 Jun 2024US$1.1tUS$164.4b-US$28,157,592,218.3728.5x-40.7x7x
Mon, 27 May 2024US$1.1tUS$164.6b-US$26,653,350,594.7223.8x-42.2x6.8x
Wed, 24 Apr 2024US$1.1tUS$164.3b-US$23,439,543,461.9720.4x-46.7x6.7x
Fri, 22 Mar 2024US$1.2tUS$164.3b-US$23,898,885,613.2121.6x-48.8x7.1x
Sun, 18 Feb 2024US$1.2tUS$169.1b-US$20,519,191,458.5815.7x-56.9x6.9x
Tue, 16 Jan 2024US$1.4tUS$204.8b-US$22,498,525,782.0018.8x-63.9x7x
Thu, 14 Dec 2023US$1.3tUS$204.7b-US$22,099,611,280.0019.6x-59.9x6.5x
Sat, 11 Nov 2023US$1.2tUS$204.5b-US$22,053,784,561.0018.5x-54.1x5.8x
Mon, 09 Oct 2023US$1.3tUS$207.4b-US$13,060,168,797.0017.2x-96.4x6.1x
Wed, 06 Sep 2023US$1.3tUS$207.5b-US$12,513,012,217.0017.2x-102x6.2x
Fri, 04 Aug 2023US$1.1tUS$183.2b-US$17,641,388,597.0014.5x-64.3x6.2x
Sun, 02 Jul 2023US$1.1tUS$186.2b-US$16,042,400,813.0013.7x-70x6x
Tue, 30 May 2023US$1.1tUS$185.9b-US$16,045,777,796.0011.2x-69.9x6x
Thu, 27 Apr 2023US$1.2tUS$198.5b-US$3,096,107,692.0012.8x-375.3x5.9x
Sat, 25 Mar 2023US$1.1tUS$199.3b-US$3,645,756,952.0013.4x-310.8x5.7x
Mon, 20 Feb 2023US$1.2tUS$202.6b-US$64,851,937.0016.5x-17789.6x5.7x
Wed, 18 Jan 2023US$1.2tUS$203.6bUS$1.7b14.6x683.1x5.8x
Fri, 16 Dec 2022US$1.2tUS$203.3bUS$1.6b14.5x734.9x5.7x
Sun, 13 Nov 2022US$1.1tUS$202.2bUS$1.1b14.6x1045.5x5.5x
Price to Earnings Ratio

1045.5x


Total Market Cap: US$1.1tTotal Earnings: US$1.1bTotal Revenue: US$202.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 24.1x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 6.7% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.58%
Healthcare1.04%
Biotech1.63%
Biotech1.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$319.869.6%
+US$15.1b		-0.6%PE26x
GILD Gilead SciencesUS$122.583.4%
+US$5.2b		33.7%PE18.8x
INSM InsmedUS$186.8811.9%
+US$4.6b		156.5%PS89.2x
INCY IncyteUS$105.7017.2%
+US$3.0b		30.6%PE17.5x
MTSR MetseraUS$71.3836.7%
+US$2.0b		n/aPB16.7x

Latest News

GILD
US$122.58
Gilead Sciences
7D
3.4%
1Y
33.7%
APLS
US$19.95
Apellis Pharmaceuticals
7D
-33.6%
1Y
-30.8%
QURE
US$26.06
uniQure
7D
-63.1%
1Y
264.0%
SLNO
US$46.87
Soleno Therapeutics
7D
-32.3%
1Y
-17.9%
AMGN
US$319.86
Amgen
7D
9.6%
1Y
-0.6%
INCY
US$105.70
Incyte
7D
17.2%
1Y
30.6%
BHVN
US$8.34
Biohaven
7D
-53.9%
1Y
-84.5%
NBIX
US$153.75
Neurocrine Biosciences
7D
11.4%
1Y
22.7%

NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value

The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.
MDGL
US$475.87
Madrigal Pharmaceuticals
7D
11.3%
1Y
34.1%
VRTX
US$417.00
Vertex Pharmaceuticals
7D
-0.05%
1Y
-15.5%
EXAS
US$69.63
Exact Sciences
7D
11.0%
1Y
27.2%
MTSR
US$71.38
Metsera
7D
36.7%
1Y
n/a
ABBV
US$216.77
AbbVie
7D
-3.7%
1Y
7.7%
INSM
US$186.88
Insmed
7D
11.9%
1Y
156.5%

INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations

Insmed's analyst price target has climbed significantly, rising by more than $30 to $204.50. Analysts cite stronger pipeline execution, improving profit margins, and expanding growth opportunities across its lead programs as key reasons for the increase.
ALNY
US$434.56
Alnylam Pharmaceuticals
7D
-3.3%
1Y
59.6%